Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion

NCT06383182 | Recruiting

• 1 other identifier: Y (2024) 054
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.

Conditions

Ischemic Stroke

Outcome Measures

Primary Outcomes (1)

• Dynamic changes in serum biomarkers after endovascular treatment

  These biomarkers will be identified based on proteomic methods

  from the baseline to immediately, 30 minutes, 6 hours, and 24 hours after endovascular treatment

Secondary Outcomes (7)

• favourable functional outcome, defined as modified Rankin Scale (mRS) 0-2

  90±7 days

• excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1

  90±7 days

• distribution of modified Rankin Scale (mRS) score

  90±7 days

• early neurological improvement, defined as 4 or more decrease in National Institute of Health stroke scale (NIHSS)

  24±8 hours

• changes in National Institute of Health stroke scale (NIHSS)

  24±8 hours

Other Outcomes (3)

• the association between cerebral circulation time (CCT) and clinical outcomes

  24±8 hours, 10±2 days, 90±7 days

• the association between serum biomarkers and clinical outcomes

  24±8 hours, 10±2 days, 90±7 days

• the association between serum biomarkers and status of vessel recanalization

  24±8 hours, 10±2 days, 90±7 days

Interventions

endovascular treatment PROCEDURE

all patients with anterior circulation large vessel occlusion will receive endovascular treatment.

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment

You may qualify if:

• Age: 18-80 years;
• Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment;
• Pre-stroke mRS: 0-1;
• Baseline NIHSS: ≥6;
• Signed informed consent.

You may not qualify if:

• The presence of contraindications to internal jugular vein cannulation;
• Receiving intravenous thrombolysis;
• Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage);
• Coagulation disorders, systemic bleeding tendency, thrombocytopenia (\<100×109/L);
• Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases;
• Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg);
• Pregnant or lactating women;
• Other conditions who are not suitable for this trial by investigator.

Sponsors & Collaborators

• General Hospital of Shenyang Military Region: lead

Study Sites (1)

General Hospital of Northern Theater Command

Shenyang, 110840, China

RECRUITING

MeSH Terms

Conditions

Ischemic Stroke

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 90 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: April 17, 2024
• First Posted: April 25, 2024
• Study Start: July 2, 2024
• Primary Completion (Estimated): December 30, 2026
• Study Completion (Estimated): December 30, 2026
• Last Updated: August 21, 2025

Record last verified: 2025-08

Locations

CN (1)